350P - Single center experience of diffuse large b-cell lymphoma patients with central nervous system relapse
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586|
Central nervous system (CNS) relapse of diffuse large B cell lymphoma (DLBCL) is relatively uncommon and nearly fatal. We analyzed characteristics of patients of DLBCL presenting with CNS relapse.
All patients of DLBCL with CNS relapse from January 2010 to December 2015 were included. Data were collected from hospital information system and analyzed for characteristics and median survival.
Twenty one patients were included in the study; 14 (66.3%) males and 7 (33.7%) were females. At the time of initial diagnosis of DLBCL, median age was 37.4 years. Twelve (57.1%) patients had stage IV; 4 (19.0%), 2 (9.5%) and 3 (14.3%) had stage III, II, I disease respectively. There was extra-nodal involvement in 16 (76.2%), high LDH in 18 (85.7%), bone marrow involvement in 8 (38.1%) and bulky disease in 5 (23.8%) patients. The calculated International Prognostic score (IPS) was 1 in 4 (19%), 2 in 9(42.9%) 3 in 8 (38.1%). Lymph nodes were involved in 11 (54.5%) patients, followed by gut involvement in 2 (9.1%), cervix in 1(4.5%), gluteal muscle in 1 (4.5%), iliac bone in 1 (4.5%), liver in 1 (4.5%), ovaries in 1(4.5%), pancreas in 1(4.5%), parotid gland in 1 (4.5%) and testes in 1 (4.5%) patients. Sixteen patients received CHOP and six received RCHOP chemotherapy. Ten (47.6%) patients received CNS prophylaxis with intrathecal methotrexate. After completion of therapy 10 (47.6%) shows complete response, 3 (14.3%) partial response and 8 (38.1%) progressed. Ten (81%) patients had relapse within 6 months after completion of chemotherapy. Seven (33.3%) patients had isolated CNS relapse. Median overall survival in all CNS relapse patients was 54 days.
DLBCL patients, developing CNS relapse had advanced stage, high LDH and extra-nodal involvement at initial presentation with short overall survival.
Clinical trial indentification
Legal entity responsible for the study
Shaukat Khanum Memorail Cancer Hospital
F. Qureshi: It was retrospective analysis of patients, no financial interest.